Trek Financial LLC Acquires New Position in TransMedics Group, Inc. $TMDX

Trek Financial LLC acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the second quarter, HoldingsChannel.com reports. The fund acquired 29,255 shares of the company’s stock, valued at approximately $3,920,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Opal Wealth Advisors LLC purchased a new stake in shares of TransMedics Group in the second quarter valued at approximately $26,000. Smartleaf Asset Management LLC boosted its stake in TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock worth $30,000 after buying an additional 135 shares during the last quarter. Quarry LP grew its holdings in TransMedics Group by 88.5% in the 1st quarter. Quarry LP now owns 592 shares of the company’s stock valued at $40,000 after buying an additional 278 shares in the last quarter. Sound Income Strategies LLC purchased a new stake in TransMedics Group in the 2nd quarter valued at $48,000. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of TransMedics Group in the 2nd quarter worth $48,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $141.77 on Wednesday. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $156.00. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. The company has a 50 day moving average price of $123.60 and a 200 day moving average price of $122.52. The stock has a market capitalization of $4.84 billion, a P/E ratio of 57.40 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The company had revenue of $143.82 million for the quarter, compared to analysts’ expectations of $145.33 million. During the same period in the prior year, the firm earned $0.12 earnings per share. The firm’s revenue was up 32.2% compared to the same quarter last year. Equities research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Transactions at TransMedics Group

In other news, insider Anil P. Ranganath sold 3,000 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total transaction of $435,660.00. Following the sale, the insider owned 13,955 shares of the company’s stock, valued at approximately $2,026,545.10. This represents a 17.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward M. Basile sold 4,142 shares of TransMedics Group stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total transaction of $540,323.90. Following the completion of the transaction, the director owned 2,866 shares of the company’s stock, valued at $373,869.70. This trade represents a 59.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 7.00% of the company’s stock.

Analysts Set New Price Targets

TMDX has been the topic of several recent research reports. Morgan Stanley boosted their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research report on Tuesday. Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a report on Wednesday, October 8th. Canaccord Genuity Group upped their price objective on TransMedics Group from $142.00 to $147.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Evercore ISI started coverage on TransMedics Group in a research report on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 price objective for the company. Finally, Needham & Company LLC restated a “buy” rating on shares of TransMedics Group in a research report on Thursday, October 30th. Seven analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $133.00.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.